Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Treasury Shares: 2024-2025

Historic Treasury Shares for Janux Therapeutics (JANX) over the last 2 years, with Sep 2025 value amounting to $699,467.

  • Janux Therapeutics' Treasury Shares rose 768.23% to $699,467 in Q3 2025 from the same period last year, while for Sep 2025 it was $699,467, marking a year-over-year increase of 768.23%. This contributed to the annual value of $341,847 for FY2024, which is N/A change from last year.
  • Latest data reveals that Janux Therapeutics reported Treasury Shares of $699,467 as of Q3 2025, which was down 0.31% from $701,652 recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Treasury Shares registered a high of $701,652 during Q2 2025, and its lowest value of $17,500 during Q2 2024.
  • For the 2-year period, Janux Therapeutics' Treasury Shares averaged around $407,360, with its median value being $472,490 (2024).
  • Data for Janux Therapeutics' Treasury Shares shows a peak YoY skyrocketed of 3,909.44% (in 2025) over the last 5 years.
  • Over the past 2 years, Janux Therapeutics' Treasury Shares (Quarterly) stood at $341,847 in 2024, then surged by 768.23% to $699,467 in 2025.
  • Its Treasury Shares was $699,467 in Q3 2025, compared to $701,652 in Q2 2025 and $603,132 in Q1 2025.